Respiratory Diseases

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.

The National Foundation for Infectious Diseases medical director appeals to the community at large to set politics and personal grievance aside and to "first, do no harm."

Your daily dose of the clinical news you may have missed.

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

Hopkins, of the National Foundation for Infectious Diseases, is frustrated by the diminished societal response to the virus' circulation including ongoing low vaccination rates.

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

A woman in her mid-50s arrives at the ED for suspected anaphylaxis; SOB has not responded to epinephrine and steroids. Does the CT scan suggest a Dx?

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.

Your daily dose of the clinical news you may have missed.

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

IDWeek 2024: Black individuals were less likely to be vaccinated against all 3 respiratory viruses than White individuals, according to new research.

Your daily dose of the clinical news you may have missed.

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

Surya Bhatt, MD, MSPH, is coprincipal investigator for the 2 pivotal phase 3 clinical trials that supported today's landmark FDA approval of dupilumab for COPD.

Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.

The positive pivotal phase 3 trial results showed improved lung function with neradomilast vs placebo and will support BI's US and global NDA submissions.

The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.

RSVPreF induced strong neutralizing responses in immunocompromised adults aged 18 years and older in substudy B of the ongoing phase 3 MONET clinical trial.

Patients largely underestimate how long a cold should last and the lingering symptoms too often prompt a request for antibiotics. Primary care, please resist!

The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.

Encouraging patients to reach out with questions may lead more to roll up their sleeves this season, Tochi Iroku-Malize, MD, told Patient Care.

Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.

The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.

Your daily dose of the clinical news you may have missed.

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.